Table 1. Baseline patient characteristics by schedule.
| Characteristic | Traditional schedule | Alternative schedule | Whole population | P value |
|---|---|---|---|---|
| No of patients | 98 | 87 | 185 | |
|
| ||||
| Male | 81 (83%) | 57 (66%) | 138 (75%) | 0.01 |
| Age | 59 (34–82) | 62 (23–80) | 60 (23–82) | 0.13 |
|
| ||||
| Race | ||||
| Caucasian | 72 (74%) | 70 (81%) | 142 (77%) | 0.54 |
| African-American | 6 (6%) | 3 (3%) | 9 (5%) | |
| Other | 20 (20%) | 14 (16%) | 34 (18%) | |
|
| ||||
| ECOG PS | ||||
| 0 | 19 (19%) | 23 (26%) | 42 (23%) | 0.43 |
| 1 | 59 (60%) | 51 (59%) | 110 (60%) | |
| ≥ 2 | 20 (20%) | 13 (15%) | 33 (12%) | |
|
| ||||
| Nephrectomy | 56 (57%) | 52 (60%) | 108 (58%) | 0.77 |
|
| ||||
| MSKCC | ||||
| Good | 4 (4%) | 6 (7%) | 10 (5%) | 0.37 |
| Intermediate | 46 (47%) | 47 (54%) | 93 (50%) | |
| Poor | 48 (49%) | 34 (39%) | 82 (44%) | |
|
| ||||
| Heng Criteria | ||||
| Favorable | 10 (10%) | 13 (15%) | 23 (12%) | 0.16 |
| Intermediate | 60 (61%) | 59 (68%) | 119 (64%) | |
| Poor | 28 (29%) | 15 (17%) | 43 (23%) | |
|
| ||||
| Disease Sites | ||||
| Lungs | 73 (75%) | 61 (70%) | 134 (72%) | 0.51 |
| Bone | 25 (26%) | 37 (43%) | 62 (34%) | 0.01 |
| Liver | 19 (19%) | 18 (21%) | 37 (20%) | 0.85 |
|
| ||||
| Number of metastases | ||||
| 1 | 33 (34%) | 25 (29%) | 58 (31%) | 0.685 |
| 2 | 37 (38%) | 38 (44%) | 75 (41%) | |
| ≥3 | 28 (29%) | 24 (28%) | 52 (28%) | |
|
| ||||
| Laboratory abnormalities | ||||
| Hgb < LLN | 74 (76%) | 65 (75%) | 139 (75%) | 1.00 |
| ANC > 7.3 K/uL | 31 (32%) | 8 (9%) | 39 (21%) | < 0.01 |
| Cor. Ca > 10 mg/dL | 20 (20%) | 20 (23%) | 40 (22%) | 0.72 |
| PLT > 440 K/uL | 16 (16%) | 10 (12%) | 26 (14%) | 0.40 |
ECOG PS = Eastern Cooperative Oncology Group performance status; MSKCC = Memorial Sloan-Kettering Cancer Center; Hgb = hemoglobin; LLN = lower limit of normal; ANC = absolute neutrophil count; Cor. Ca = corrected calcium; PLT = platelets